Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that semaglutide significantly reduced body weight in almost 80% of obese PCOS patients unresponsive to lifestyle changes, often normalizing menstrual cycles with few side effects.

This study highlights a potential association between semaglutide, a diabetes medication, and increased reports of hair loss, with researchers calling for more rigorous clinical trials to confirm and better understand the risk.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In this observational study, researchers found that new users of tirzepatide experienced a higher incidence of alopecia compared to semaglutide users over a 12-month period, with increased risk persisting even when accounting for achieved weight loss and treatment duration.

This study reviews the role of semaglutide in obesity management, emphasizing its substantial weight-loss and metabolic benefits in diverse patients, with a focus on its mechanisms, dosing, efficacy, and safety.